Get the Stockscreener App
2.78
9.45%
-0.29
Pre-market:
2.89
0.11
+3.96%
Incannex Healthcare Inc stock is traded at $2.78, with a volume of 423.23K.
It is down -9.45% in the last 24 hours and down -66.18% over the past month.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
See More
Previous Close:
$3.07
Open:
$2.99
24h Volume:
423.23K
Relative Volume:
1.02
Market Cap:
$38.85M
Revenue:
$12,000
Net Income/Loss:
$-48.50M
P/E Ratio:
-0.1629
EPS:
-17.0687
Net Cash Flow:
$-19.78M
1W Performance:
-16.01%
1M Performance:
-66.18%
6M Performance:
-84.86%
1Y Performance:
-88.42%
1-Day Range:
$2.7775
$3.02
1-Week Range:
$2.7775
$3.30
52-Week Range:
$2.40
$49.80
Incannex Healthcare Inc Stock (IXHL) Company Profile
Name
Incannex Healthcare Inc
Sector
Phone
61 409 840 786
Address
8 CENTURY CIRCUIT, NORWEST NSW
Compare IXHL vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IXHL
Incannex Healthcare Inc
|
2.78 | 38.85M | 12,000 | -48.50M | -19.78M | -17.07 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Incannex Healthcare Inc Stock (IXHL) Latest News
Incannex says it holds $75 million in cash with zero debt after financing - MSN
Incannex Healthcare Company Profile & Introduction - Moomoo
IXHL Stock Price, Quote & Chart | INCANNEX HEALTHCARE INC (NASDAQ:IXHL) - ChartMill
IXHL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Incannex reports $75M cash position with no debt after financing By Investing.com - Investing.com South Africa
Incannex reports $75M cash position with no debt after financing - Investing.com Australia
Incannex Highlights $75 Million Cash, No Debt, and Advances IHL-42X and PSX-001 Clinical Programs - Minichart
Incannex approves 1-for-30 reverse stock split to regain Nasdaq compliance - MSN
Incannex Healthcare Inc. (IXHL) implements 1-for-30 reverse split effective February 26 - MSN
Incannex Healthcare Strengthens Cash Position, Highlights Clinical Pipeline - TipRanks
Incannex Highlights $75M Cash, No Debt as It Funds DReAMzz Phase 2 and Advances IHL-42X - TradingView
Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development - The Manila Times
Incannex (Nasdaq: IXHL) highlights $75M cash, no debt and advancing trials - Stock Titan
Market values Incannex at $46M despite $75M in cash - Stock Titan
Incannex regains Nasdaq compliance with minimum bid price By Investing.com - Investing.com South Africa
Incannex Healthcare Regains Nasdaq Compliance and Advances Clinical Pipeline with Strong Cash Position - Minichart
Incannex regains Nasdaq compliance with minimum bid price - Investing.com
Incannex regains compliance with Nasdaq minimum bid price requirement - marketscreener.com
Incannex Regains Nasdaq Compliance, Strengthening Pipeline Progress - TipRanks
Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement - The Manila Times
Incannex Healthcare (NASDAQ: IXHL) restores Nasdaq bid price compliance, highlights $75M cash - Stock Titan
Biotech Incannex clears Nasdaq listing hurdle, holds $75M cash and no debt - Stock Titan
Incannex outlines dose-optimization study for sleep apnea treatment - MSN
Incannex Stock Slides As $10 Million Capital Raise Funds Next Study For Sleep Apnea Treatment - Yahoo Finance UK
Incannex Healthcare Announces $10 Million Direct Offering - The Globe and Mail
Dow Tumbles Over 1%; US Weekly Jobless Claims Fall - Sahm
Why did IXHL stock slump 20% in pre-market today? - MSN
Incannex plans dose-optimization study for sleep apnea drug By Investing.com - Investing.com South Africa
IHL.AX Incannex Healthcare (ASX) A$0.041 intraday 13 Mar 2026: Phase 2 news drives volume - Meyka
Incannex plans dose-optimization study for sleep apnea drug - Investing.com Australia
Incannex Healthcare (NASDAQ: IXHL) sells 1.997M units for ~$9M - Stock Titan
Will Incannex Healthcare Inc benefit from AI trends2026 Retail Activity & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Incannex Updates Clinical Pathway for Sleep Apnea Drug Candidate IHL-42X - Sleep Review
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Incannex Healthcare stock drops 20% after $10 mn private placement | Tap to know more | Inshorts - Inshorts
Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes - Bitget
Why Did IXHL Stock Slump 20% In Pre-Market Today? - Asianet Newsable
Incannex prices 2M shares at $5.00 in registered direct offering - TipRanks
Incannex Healthcare prices $10M registered direct offering - MSN
Incannex announces enhanced development strategy for IHL-42X - TipRanks
Why Did IXHL Stock Slump 35% Today? - Stocktwits
Incannex Healthcare Inc Shares Drop 20% After $10 Million Placement Announcement - Intellectia AI
Incannex Highlights Enhanced Phase 2 Study and Updates - TipRanks
Incannex Healthcare Inc. (NASDAQ: IXHL) officially announced that the company has completed the pricing of a registered direct offering with a total size of 10 million dollars. - Bitget
Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
Incannex Healthcare Inc Stock (IXHL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):